Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial

Por Loibl, Sibylle, Doering, Gabriele, Müller, Lothar, Grote-Metke, Albert, Müller, Roberto, Tomé, Oliver, Wiest, Wolfgang, Maisch, Andrea, Nekljudova, Valentina, von Minckwitz, Gunter
Publicado em 2011

NCO-sP(EO-stat-PO) Coatings on Gold Sensors—a QCM Study of Hemocompatibility

Por Sinn, Stefan, Eichler, Mirjam, Müller, Lothar, Bünger, Daniel, Groll, Jürgen, Ziemer, Gerhard, Rupp, Frank, Northoff, Hinnak, Geis-Gerstorfer, Jürgen, Gehring, Frank K., Wendel, Hans P.
Publicado em 2011

ABC3 Consensus: Assessment by a German Group of Experts

Por Thomssen, Christoph, Augustin, Doris, Ettl, Johannes, Haidinger, Renate, Lück, Hans-Joachim, Lüftner, Diana, Marmé, Frederik, Marschner, Norbert, Müller, Lothar, Overkamp, Friedrich, Ruckhäberle, Eugen, Thill, Marc, Untch, Michael, Wuerstlein, Rachel, Harbeck, Nadia
Publicado no Breast Care (Basel) (2016)

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type...

Por Eng, Cathy, Bessudo, Alberto, Hart, Lowell L., Severtsev, Aleksey, Gladkov, Oleg, Müller, Lothar, Kopp, Mikhail V., Vladimirov, Vladimir, Langdon, Robert, Kotiv, Bogdan, Barni, Sandro, Hsu, Ching, Bolotin, Ellen, von Roemeling, Reinhard, Schwartz, Brian, Bendell, Johanna C.
Publicado no Int J Cancer (2016)

Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial

Por Chekerov, Radoslav, Harter, Philipp, Fuxius, Stefan, Hanker, Lars Christian, Woelber, Linn, Müller, Lothar, Klare, Peter, Abenhardt, Wolfgang, Nedkova, Yoana, Yalcinkaya, Isil, Heinrich, Georg, Sommer, Harald, Mahner, Sven, Wimberger, Pauline, Koensgen-Mustea, Dominique, Richter, Rolf, Oskay-Oezcelik, Gülten, Sehouli, Jalid
Publicado no Gynecol Oncol Res Pract (2017)

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

Por Harbeck, Nadia, Saupe, Steffen, Jäger, Elke, Schmidt, Marcus, Kreienberg, Rolf, Müller, Lothar, Otremba, Burkhard Joerg, Waldenmaier, Dirk, Dorn, Julia, Warm, Mathias, Scholz, Michael, Untch, Michael, de Wit, Maike, Barinoff, Jana, Lück, Hans-Joachim, Harter, Philipp, Augustin, Doris, Harnett, Paul, Beckmann, Matthias W., Al-Batran, Salah-Eddin
Publicado no Breast Cancer Res Treat (2016)

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

Por Proetel, Ulrike, Pletsch, Nadine, Lauseker, Michael, Müller, Martin C., Hanfstein, Benjamin, Krause, Stefan W., Kalmanti, Lida, Schreiber, Annette, Heim, Dominik, Baerlocher, Gabriela M., Hofmann, Wolf-Karsten, Lange, Elisabeth, Einsele, Hermann, Wernli, Martin, Kremers, Stephan, Schlag, Rudolf, Müller, Lothar, Hänel, Mathias, Link, Hartmut, Hertenstein, Bernd, Pfirrmann, Markus, Hochhaus, Andreas, Hasford, Joerg, Hehlmann, Rüdiger, Saußele, Susanne
Publicado em 2014